EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system

Zhu Wang iD, Guoping Gan iD, Haiping Yao iD

Acta Pharmaceutica · 2025

DOI: 10.2478/acph-2026-0001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica, 2025. Verfasst von Zhu Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Pediatrics, The First College of Clinical Medical Science China Three Gorges University & Yichang Central People's Hospital Yichang, H…. Hauptthemen laut MEDLINE: Tigecycline, Tetracyclines, Adverse Drug Reaction Reporting Systems, Anti-Bacterial Agents. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assessed the gastrointestinal (GI) safety profiles of tigecycline, omadacycline, and eravacycline through a retrospective disproportionality analysis of reports submitted to the FDA Adverse Event Reporting System (FAERS) between the second quarter of 2005 and the first quarter of 2024. Among 3,261 adverse event reports associated with these agents, 809 (24.8 %) involved gastrointestinal disorders, with tigecycline accounting for the largest proportion (588 reports), followed by omadacycline (197) and eravacycline (24). Disproportionality analysis revealed that gastrointestinal disorders ranked among the top three system organ classes for all three drugs, with positive signals observed for tigecycline (ROR = 1.63), omadacycline (ROR = 3.04), and eravacycline (ROR = 1.79), the strongest association being with omadacycline. While most GI events were consistent with known safety information, several unexpected signals were identified, including gastrointestinal haemorrhage, melena, small-intestinal obstruction, tongue discolouration, and intestinal perforation for tigecycline, as well as lip swelling and tongue discolouration for omadacycline. The median onset times of GI events were 4, 0, and 2.5 days for tigecycline, omadacycline, and eravacycline, respectively, with nearly half of the events occurring within three days of treatment initiation. These findings reveal distinct GI safety patterns among newer tetracycline-derived antibiotics and underscore the importance of early and route-specific monitoring in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TigecyclineTetracyclinesAdverse Drug Reaction Reporting SystemsAnti-Bacterial AgentsGastrointestinal DiseasesHumansUnited StatesUnited States Food and Drug AdministrationRetrospective StudiesMiddle AgedMaleFemaleAdultAgedAdolescentChildYoung Adult

Stichwörter der Autor:innen

FAERSeravacyclinegastrointestinal safetyomadacyclinepharmaco-vigilancetigecycline

Substanzen

TigecyclineTetracyclinesAnti-Bacterial Agentseravacyclineomadacycline

Autor:innen und Institutionen

  • 1Department of Pediatrics, The First College of Clinical Medical Science China Three Gorges University & Yichang Central People's Hospital Yichang, Hubei 443003, P. R. China.
  • 3College of Pharmacy, Hubei University of Chinese Medicine Wuhan, Hubei 430065, P. R. China.
  • 2Department of Pharmacy, The First College of Clinical Medical Science China Three Gorges University & Yichang Central People's Hospital Yichang, Hubei 443003, P. R. China.

ORCID-Profile: Zhu Wang, Guoping Gan, Haiping Yao

Zitieren

APA

Wang, Z., Gan, G., & Yao, H. (2025). Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system. Acta Pharmaceutica. https://doi.org/10.2478/acph-2026-0001

Vancouver

Wang Z, Gan G, Yao H. Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system. Acta Pharmaceutica. 2025. doi:10.2478/acph-2026-0001

BibTeX
@article{Wang2025,
  author = {Wang, Zhu and Gan, Guoping and Yao, Haiping},
  title = {Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system},
  journal = {Acta Pharmaceutica},
  year = {2025},
  doi = {10.2478/acph-2026-0001}
}
Kostenlos starten →